Table 1.
Characteristics of the analyzed cohort of patients with COVID-19 at admission to hospital.
| N (%), Median (IQR) | |
|---|---|
| Total number of patients | 3812 |
| Age (years) | 74 (64–82) |
| Sex | |
| Female | 1664 (43.7%) |
| Male | 2148 (56.3%) |
| Arterial hypertension | |
| Yes | 2658 (69.7%) |
| No | 1154 (30.3%) |
| Diabetes mellitus | |
| Yes | 1154 (30.3%) |
| No | 2658 (69.7%) |
| Obesity (Body mass index ≥ 30 kg/m2) | |
| Yes | 1023 (28.6%) |
| No | 2554 (71.4%) |
| Congestive heart failure | |
| Yes | 617 (16.2%) |
| No | 3195 (82.8%) |
| Chronic kidney disease | |
| Yes | 474 (12.4%) |
| No | 3338 (87.6%) |
| Chronic liver disease | |
| Yes | 106 (2.8%) |
| No | 3706 (97.2%) |
| Liver cirrhosis | |
| Yes | 49 (1.3%) |
| No | 3763 (98.7%) |
| Charlson comorbidity index | 4 IQR (3–6) |
| Alcohol use | |
| Yes | 207 (5.4%) |
| No | 3605 (94.6%) |
| Smoking | |
| Yes | 434 (11.4%) |
| No | 3378 (88.6%) |
| Number of drugs in chronic therapy | 5 (3–8) |
| Statin use | |
| Yes | 911 (23.9%) |
| No | 2901 (76.1%) |
| Antibiotic therapy before admission | |
| Yes | 1285 (33.7%) |
| No | 2527 (66.3%) |
| Oral anticoagulant therapy | |
| Yes | 1049 (27.5%) |
| No | 2763 (72.5%) |
| AST (U/L) | 41 (28–64) |
| ALT (U/L) | 31 (19–52) |
| GGT (U/L) | 42 (24–81) |
| ALP (U/L) | 72 (56–97) |
| Total bilirubin (umol/L) | 11.4 (8.6–15.9) |
| Albumin (g/L) | 32 (28–35) |
| Prothrombin time (%, Quick) * | 100% (89–109%) |
| Liver blood tests (any) | |
| Normal level | 958 (25.1%) |
| Deranged | 2854 (74.9%) |
| White blood cell count (×109/L) | 8 (5.8–11.2) |
| Hemoglobin (g/L) | 128 (113–141) |
| Platelets (×109/L) | 221 (163–297) |
| C-reactive protein (mg/L) | 88.7 (39.5–151) |
| Ferritin (ug/L) | 711 (386–1289) |
| D-dimers (mg/L) | 1.42 (0.73–3.6) |
| Day of disease on admission | 5 (1–9) |
| ECOG status | 3 (1–4) |
| Pneumonia | |
| Yes | 3390 (88.9%) |
| No | 422 (11.1%) |
| Oxygen therapy | |
| Yes | 3136 (82.3%) |
| No | 676 (17.7%) |
| MEWS severity | |
| Mild | 392 (10.3%) |
| Moderate | 196 (5.1%) |
| Severe | 2652 (69.6%) |
| Critical | 572 (15%) |
| ICU admission | |
| Yes | 881 (23.1%) |
| No | 2931 (76.9%) |
| Mechanical ventilation | |
| Yes | 659 (17.3%) |
| No | 3153 (82.7%) |
| 30-day mortality | |
| Yes | 1315 (34.5%) |
| No | 2497 (65.5%) |
Table legend: AST—aspartate aminotransferase, ALT—alanine aminotransferase, GGT—gamma-glutamyl transferase, ALP—alkaline phosphatase, IQR—interquartile range, ICU—intensive care unit, MEWS—modified early warning score, ECOG—Eastern Cooperative Oncology Group. * Prothrombin time values calculated for the patients not receiving oral anticoagulants.